Fly News Breaks for February 26, 2020
Feb 26, 2020 | 08:50 EDT
As reported previously, Canaccord analyst John Newman upgraded Regeneron (REGN) to Buy from Hold. The analyst noted its competition decreased when the ASRS warned about 14 cases of vasculitis in patients that received Novartis's (NVS) Beovu. The analyst noted the report should reduce the EYLEA competitive concerns in the wet AMD space. Newman raised his price target to $550 from $409 on Regeneron shares.
News For REGN;NVS From the Last 2 Days
Apr 12, 2021 | 09:28 EDT
Benchmark analyst Aydin Huseynov expects full FDA approval of Regeneron's (REGN) REGEN-COV could be coming within weeks, possibly in both 2.4g and 1.2g doses, citing the 70% reduction in risk of hospitalization or death in a 4,600-patient REGEN-COV randomized placebo-controlled trial in non-hospitalized COVID-19 patients as well as what he sees as "an apparent preference" for Regeneron's cocktail over Eli Lilly's (LLY). Huseynov has a Buy rating and $590 price target on Regeneron shares.